The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•4 May 2026•

1 min read

Caris Life Sciences Secures MolDX Approval for ChromoSeq Genetic Assay

Key Facts

1Caris ChromoSeq received MolDX approval, supporting clinical access and reimbursement for myeloid malignancy profiling.

Caris Life Sciences has announced that its ChromoSeq assay, a whole genome tumor profiling technology, has received approval from the Molecular Diagnostic Services (MolDX) program. This regulatory milestone is significant as it secures Medicare coverage and reimbursement, facilitating broader clinical access for patients with myeloid malignancies. The approval validates the clinical utility of the test, which is essential for the company's commercial scaling within the precision medicine market. By utilizing next-generation sequencing, ChromoSeq provides a comprehensive view of genetic alterations to guide personalized treatment decisions. This development underscores growing regulatory confidence in the company's diagnostic capabilities. Consequently, the move strengthens the company's competitive positioning in the biotechnology sector by securing critical reimbursement pathways.

Sources: